EICHORCondition: Soft Tissue Sarcoma · Sponsor: Institut Claudius Regaud
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a phase II, multicenter, non-randomized study. The main objective is to evaluate the treatment with hypofractionated radiation therapy in neo-adjuvant situations on wound healing in a population of aged patients (≥ 70 years old) or ≥ 65 years of age defined as "fragile" and treated for soft tissue sarcoma. A maximum of 48 evaluable patients will be included in this study. The patients will receive an hypofractionated radiation therapy prior to conservative surgery. Each patient will be followed for up to 3 years after the end of complete treatment (radiotherapy + surgery).
This description comes directly from the study's public registry record.
Justine ATTAL KHALIFA · 05 31 15 54 38 · AttalKhalifa.Justine@iuct-oncopole.fr
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Patient with histologically confirmed soft tissue sarcoma of the limbs or trunk. 2. Indication for neo-adjuvant or adjuvant radiotherapy. 3. Patient aged ≥ 70 years with a performance status ECOG ≤ 2 and/or aged 65 to 70 years with an ECOG of 2 and identified by the investigator as "fragile". 4. Patient affiliated to a Social Health Insurance in France. 5. Patient able to participate and willing to give informed consent prior performance of any study-related procedures. Exclusion Criteria: 1. Retroperitoneal, ORL and visceral sarcomas. 2. Previous radiotherapy in the area. 3. Metastatic disease. 4. Concomitant or sequential chemotherapy. 5. Patient requiring total surgery (amputation). 6. Other cancer under treatment. 7. Any condition or pathology contraindicating MRI. 8. Any psychological, familial, geographic or social situation, potentially preventing the provision of informed consent or compliance to study procedure. 9. Patients included in another therapeutic interventional trial. 10. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Institut Bergonie | Bordeaux, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Chu de Limoges | Limoges, France | Recruiting |
| Centre Leon Berard | Lyon, France | Recruiting |
| Institut Regional Du Cancer de Montpellier | Montpellier, France | Recruiting |
| Institut Curie | Paris, France | Recruiting |
| Chu de Poitiers | Poitiers, France | Recruiting |
| Institut de Cancerologie de L'Ouest | Saint-Herblain, France | Recruiting |
| Chu de Toulouse | Toulouse, France | Recruiting |
| IUCT-O | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06022159